Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics, Inc. (FHTX)
:FHTX
FHTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.94 - $10.25
Previous CloseN/A
Volume24.60K
Average Volume (3M)137.33K
Market Cap
$278.71M
Enterprise Value$119.78M
Total Cash (Recent Filing)$198.66M
Total Debt (Recent Filing)$23.70M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Nov 11, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding55,741,370
10 Day Avg. Volume121,797
30 Day Avg. Volume137,330
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-5.69
Price to Sales (P/S)11.46
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue4.96
Enterprise Value/Gross Profit7.21
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$8.67Price Target Upside73.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Preclinical SuccessPreclinical data showed that FHD-909 combined with pembrolizumab resulted in meaningful tumor regression, underscoring its potential in treating NSCLC.
Strategic CollaborationsFoghorn's partnership with Lilly for FHD-909 has been a major focus of investor interest, highlighting its strategic importance.
Therapeutic AdvancementsTargeted protein degradation and induced proximity are rapidly reshaping the therapeutic landscape, potentially marking a significant inflection point in precision medicine.
Bears Say
Financial PerformanceFoghorn reported collaboration revenues of $6M and $3M in separate quarters, both below the $10M estimate, indicating potential financial challenges.
Revenue ShortfallFoghorn's Q4 collaboration revenue was $3M, significantly below the expected $10M, raising concerns about financial performance.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics, Inc.’s price range in the past 12 months?
Foghorn Therapeutics, Inc. lowest stock price was $2.94 and its highest was $10.25 in the past 12 months.
What is Foghorn Therapeutics, Inc.’s market cap?
Foghorn Therapeutics, Inc.’s market cap is $278.71M.
When is Foghorn Therapeutics, Inc.’s upcoming earnings report date?
Foghorn Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2025 which is in 95 days.
How were Foghorn Therapeutics, Inc.’s earnings last quarter?
Foghorn Therapeutics, Inc. released its earnings results on Aug 05, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.071.
Is Foghorn Therapeutics, Inc. overvalued?
According to Wall Street analysts Foghorn Therapeutics, Inc.’s price is currently Undervalued.
Does Foghorn Therapeutics, Inc. pay dividends?
Foghorn Therapeutics, Inc. does not currently pay dividends.
What is Foghorn Therapeutics, Inc.’s EPS estimate?
Foghorn Therapeutics, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Foghorn Therapeutics, Inc. have?
Foghorn Therapeutics, Inc. has 55,741,370 shares outstanding.
What happened to Foghorn Therapeutics, Inc.’s price movement after its last earnings report?
Foghorn Therapeutics, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went down -2.724%.
Which hedge fund is a major shareholder of Foghorn Therapeutics, Inc.?
Currently, no hedge funds are holding shares in FHTX
Foghorn Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (73.40% Upside)
$8.67 (73.40% Upside)
Hedge Fund Trend
Increased
By 62.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.07%
12-Months-Change
Fundamentals
Return on Equity
322.49%
Trailing 12-Months
Asset Growth
-31.15%
Trailing 12-Months
Company Description
Foghorn Therapeutics, Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$8.67
▲(73.40% Upside)
Technical Analysis
Tonix Pharma
―
Astria Therapeutics
―
Monte Rosa Therapeutics
―
Vigil Neuroscience Inc
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.16% Insiders
9.88% Mutual Funds
45.59% Other Institutional Investors
37.71% Public Companies and Individual Investors